Evidence overview
Berberine
Berberine is a plant alkaloid with growing clinical research on glycemic control, lipid profiles, weight management, and gut microbiome modulation. The metabolic-effects literature is the most-developed area and has attracted comparisons to metformin in trial designs. Bioavailability of standard berberine HCl is poor, which is one of the practical questions consumers face when selecting a product.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Plant alkaloid found in goldenseal, Oregon grape, barberry, and several other plants. Primary mechanism...
Study coverage
Study coverage by goal
PubMed counts for Berberine grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Berberine.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Berberine is a plant alkaloid found in goldenseal, Oregon grape, barberry, and other plants. The supplement literature spans glycemic control in type 2 diabetes and prediabetes (the most-studied area, with multiple meta-analyses and a recent umbrella review), lipid profiles and lipid-lowering effects (where berberine has been positioned as a nutraceutical alternative in some clinical contexts), weight management and body composition, blood pressure, polycystic ovary syndrome (PCOS), gut microbiome modulation, and inflammatory biomarkers. The mechanism centers on AMPK activation, which is part of why berberine is frequently compared to metformin in trial designs.
The outcome dimensions covered most heavily are type 2 diabetes-related glycemic markers (fasting glucose, HbA1c, insulin resistance - the most-anchored research area), lipid profiles in hyperlipidemia and metabolic syndrome, weight and waist circumference in overweight and obese populations, PCOS metabolic and reproductive markers, and inflammatory biomarkers. Cardiovascular safety and hard cardiovascular outcomes (events, mortality) are not the focus of berberine research; the evidence base concentrates on surrogate markers rather than hard endpoints, which is a recurring methodological limitation of the literature.
Demographically, the literature concentrates on adults with metabolic syndrome, type 2 diabetes, or prediabetes; smaller research streams in PCOS focus on reproductive-age women. Bioavailability is a major practical issue: standard berberine HCl has poor oral absorption (typically only a few percent), which has driven development of absorption-enhanced formulations including phytosome and dihydroberberine. Trial dosing typically uses 500 mg three times daily of standard berberine, but enhanced formulations claim equivalent effects at lower doses; head-to-head trial data on form selection is thinner than the marketing implies.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Berberine is generally well-tolerated at typical supplemental doses (500-1,500 mg/day divided), though gastrointestinal adverse effects are unusually common: constipation, diarrhea, abdominal cramping, and nausea affect a substantial fraction of users at higher doses and during initiation. No tolerable upper limit has been established. Drug interactions are unusually consequential for berberine: the compound is a strong inhibitor of CYP3A4, CYP2D6, and P-glycoprotein, which means it can affect blood levels of many medications including statins, calcium channel blockers, immunosuppressants (cyclosporine, tacrolimus), and many others. Theoretical additive hypoglycemia with metformin, insulin, and sulfonylureas is documented in case reports. People on any prescription medication, especially diabetes medications or narrow-therapeutic-index drugs, should consult a clinician before starting.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Umbrella meta-analysis covering berberine's primary metabolic use case - the highest-level synthesis available for the supplement's most-studied research area.
View on PubMedJoint position statement from two Italian expert societies (Society of Diabetology and Society for the Study of Arteriosclerosis) on nutraceuticals for hypercholesterolemia, including berberine. The clearest practice-guideline-level positioning for berberine's lipid-lowering use.
View on PubMedDose-response meta-analysis on berberine for obesity indices, providing the modern reference for the supplement's weight-management application alongside its metabolic-marker effects.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the berberine literature at a general level. It does not address which formulation (standard berberine HCl, phytosome, or dihydroberberine) is right for your specific goal, what dose to use given the chosen formulation, whether your medication list flags any CYP-related or hypoglycemia interactions, or whether berberine fits with your specific metabolic context. The drug-interaction question is the single most-consequential practical issue for berberine, which makes the personalized report unusually useful here.
Personalized to you
Get a personalized Berberine report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Berberine materially updates. No account required.